Correction: Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis.

Lin, Tzu-Hua; Lee, Soo Ok; Niu, Yuanjie; Xu, Defeng; Liang, Liang; Li, Lei; Yeh, Shauh-Der; Fujimoto, Naohiro; Yeh, Shuyuan; Chang, Chawnshang

Correction: Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9^® lead to promotion versus suppression of prostate cancer metastasis.

Lin, Tzu-Hua; Lee, Soo Ok; Niu, Yuanjie; Xu, Defeng; Liang, Liang; Li, Lei; Yeh, Shauh-Der; Fujimoto, Naohiro; Yeh, Shuyuan; Chang, Chawnshang.

J Biol Chem ; 295(46): 15796, 2020 Nov 13.

Article de En | MEDLINE | ID: mdl-33188084

Texte intégral

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667975
https://dx.doi.org/10.1074/jbc.AAC120.016502

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: J Biol Chem Année: 2020 Type de document: Article